Proto-Oncogene Proteins B-raf

• 

  Subject Areas on Research

  • A Diffuse Leptomeningeal Glioneuronal Tumor Without Diffuse Leptomeningeal Involvement: Detailed Molecular and Clinical Characterization. 
  • A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. 
  • A Multivariate Computational Method to Analyze High-Content RNAi Screening Data. 
  • A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. 
  • A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. 
  • ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium. 
  • Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer. 
  • Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. 
  • Advanced Melanoma: Resistance Mechanisms to Current Therapies. 
  • An Unusual Ganglioglioma with Pseudopapillary Features and PRKAR2B-BRAF Fusion. 
  • An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. 
  • Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. 
  • BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. 
  • BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. 
  • BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. 
  • BRAF in melanoma: current strategies and future directions. 
  • BRAF polymorphisms and the risk of ovarian cancer of low malignant potential. 
  • BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. 
  • Benign nodal nevi frequently harbor the activating V600E BRAF mutation. 
  • Beta2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-kappaB-independent mechanisms. 
  • Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. 
  • Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer. 
  • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 
  • Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment? 
  • Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. 
  • Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. 
  • Clinical correlates of NRAS and BRAF mutations in primary human melanoma. 
  • Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. 
  • Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles. 
  • Colon cancer, version 3.2014. 
  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. 
  • Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. 
  • Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. 
  • Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. 
  • Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. 
  • Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer. 
  • Copper is required for oncogenic BRAF signalling and tumorigenesis. 
  • Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease. 
  • Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors 
  • Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. 
  • Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas. 
  • Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. 
  • Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma. 
  • Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. 
  • Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup. 
  • ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. 
  • Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades. 
  • Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. 
  • Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). 
  • Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. 
  • Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. 
  • Exposure to flame retardant chemicals and occurrence and severity of papillary thyroid cancer: A case-control study. 
  • Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. 
  • Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. 
  • Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). 
  • Genetic convergence of rare lymphomas. 
  • Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. 
  • Genome-wide high resolution DNA profiling of hairy cell leukaemia. 
  • Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis. 
  • Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • Histological and molecular evaluation of patient-derived colorectal cancer explants. 
  • Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. 
  • ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. 
  • Identification of recurrent USP48 and BRAF mutations in Cushing's disease. 
  • Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature. 
  • Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. 
  • Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. 
  • KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. 
  • LGR5 is associated with tumor aggressiveness in papillary thyroid cancer. 
  • Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. 
  • Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. 
  • Melanoma brain metastasis: overview of current management and emerging targeted therapies. 
  • Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. 
  • Methylation profiling of paediatric pilocytic astrocytoma reveals variants specifically associated with tumour location and predictive of recurrence. 
  • MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. 
  • Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. 
  • Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. 
  • Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. 
  • Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. 
  • Molecular profile and copy number analysis of sporadic colorectal cancer in Taiwan. 
  • Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults. 
  • Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. 
  • Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. 
  • Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. 
  • Mutations of the BRAF gene in human cancer. 
  • NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. 
  • New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma. 
  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. 
  • Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. 
  • Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. 
  • Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. 
  • Overcoming MCL-1-driven adaptive resistance to targeted therapies. 
  • PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes. 
  • Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. 
  • Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas. 
  • Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. 
  • Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. 
  • Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. 
  • Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. 
  • Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma. 
  • Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma. 
  • Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. 
  • Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. 
  • Targeting BRAF-mutant glioma: reflections on the ROAR trial. 
  • Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. 
  • Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. 
  • The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. 
  • The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. 
  • The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. 
  • The limitations of imaging response criteria. 
  • Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting. 
  • Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. 
  • Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma. 
  • Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. 
  • Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects. 
  • Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma. 
  • mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • McCall, Shannon Jones, Associate Professor of Pathology, Pathology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics